Open access
Oct 2026
Optimal timing of thoracic radiotherapy with osimertinib in unresectable EGFR-mutant non-small cell lung cancer
Findings indicate that the interval between osimertinib and TRT initiation is an independent prognostic factor for EGFR-mutant NSCLC, with a non-linear J-shaped association with survival.
Meng-Ting Lai, Yan-Hua Zhou, Wei-Li Yi et al.
· Oncology Letters · 0 citations